UroGen Pharma Stock Forecast

Stock Price Forecast

According to 7 analysts polled by S&P Global, UroGen Pharma stock has a consensus rating of "Strong Buy" and an average price target of $36.43. The average 1-year stock price forecast is 36.19% higher than the current stock price, while the lowest is $18 (-32.71%) and the highest is $45 (+68.22%).

Price Target: $36.43 (+36.19%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$18	$36.43	$40	$45
Change	-32.71%	+36.19%	+49.53%	+68.22%

Analyst Ratings

The average analyst rating for UroGen Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	6	6	6	6	6	5
Buy	1	1	1	1	1	1
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	8	8	8	8	7

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Ram Selvaraju H.C. Wainwright	H.C. Wainwright	Buy Reiterates $45	Buy	Reiterates	$45	+68.22%	Jun 3, 2026
Leland Gershell Oppenheimer	Oppenheimer	Buy Reiterates $40	Buy	Reiterates	$40	+49.53%	May 19, 2026
Paul Choi Goldman Sachs	Goldman Sachs	Hold Maintains $18	Hold	Maintains	$18	-32.71%	May 18, 2026
Tara Bancroft TD Cowen	TD Cowen	Buy Maintains $35	Buy	Maintains	$35	+30.84%	May 15, 2026
Kevin DeGeeter Ladenburg Thalmann & Co.	Ladenburg Thalmann & Co.	Buy Initiates $43	Buy	Initiates	$43	+60.75%	May 11, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

265.94M

from 109.79M

142.23%

from 109.79M

Revenue Next Year

419.77M

from 265.94M

57.84%

from 265.94M

EPS This Year

-0.91

from -3.19

EPS Next Year

1.23

from -0.91

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	48.04M	64.36M	82.71M	90.40M	109.79M	265.94M
Revenue Growth	307.17%	33.96%	28.52%	9.29%	21.45%	142.23%
Gross Profit	42.89M	56.70M	73.35M	81.52M	97.34M	239.17M
Gross Margin	89.27%	88.11%	88.68%	90.18%	88.66%	89.93%
Operating Income	-92.29M	-79.04M	-65.54M	-95.68M	-124.86M	-11.01M
Net Income	-110.82M	-109.78M	-102.24M	-126.87M	-153.49M	-45.07M
EPS	-	-	-	-	-3.19	-0.91
Free Cash Flow	-44.14M	-42.79M	-35.16M	-46.83M	-99.42M	-8.50M
No. Analysts	-	-	-	-	-	8

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	303.5M
Avg	265.9M
Low	241.1M

Revenue Growth

Revenue Growth	2026	2027	2028
High	176.4%
Avg	142.2%
Low	119.6%

EPS Forecast

EPS	2026	2027	2028
High	-0.26
Avg	-0.91
Low	-1.70

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-